Abstract
To address the unmet need for scalable solutions for lifestyle treatment, we developed a new digital method to promote behavioral change. Here we report that patients with type-2 diabetes in Sweden (n = 331) exposed to the intervention have significantly improved HbA1c during a median follow-up of 1038 days (4 mmol/mol compared with matched controls; P = 0.009). This is paralleled by reduced body weight, ameliorated insulin secretion, increased physical activity, and cognitive eating restraints. Participants with high BMI and insulin resistance have an even larger response, as have non-risk allele carriers for the FTO gene. The findings open a new avenue for scalable lifestyle management with sustained efficacy and highlight a previously unrecognized opportunity for digital precision treatment based on genetics and individual pathophysiology. ClinicalTrials.gov NCT04624321.
| Original language | English |
|---|---|
| Article number | 199 |
| Journal | npj Digital Medicine |
| Volume | 6 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2023 Dec |
Bibliographical note
Funding Information:This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement TRANSLATIONAL, 866510). The study was also supported by the Swedish Research Council (2022-01301), the Knut and Alice Wallenberg Foundation, and Sydvästra Skånes Diabetesförening. We thank Louise Qvist, Maria Fälemark, Helene Ferm, and Jessica Hedin for managing study visits, as well as Jasmina Kravic, Johan Hultman, Leif Groop, and the ANDIS steering committee for support on ANDIS-related data. We also thank the patients and colleagues who participated in the development and evaluation of the tool.
Publisher Copyright:
© 2023, The Author(s).
Subject classification (UKÄ)
- Endocrinology and Diabetes
